Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Veracyte, Inc.NASDAQ: VCYT
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $24.28M rose 260.3% year over year, ahead of the +184.0% change in trailing-twelve-month EBITDA. Sequentially, it fell 31.4% from the prior quarter.
Context
- EBITDA amounted to 17.3% of revenue in FY2025, up 6.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $215.5M (+140.5%) for the fiscal year ending Dec 2026, a step up from the +82.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24.28M-31.4% QoQ
- Last fiscal yearDec 2025
- $89.62M+82.1% YoY
- LTMJun 2026
- $129.77M+184.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +260.3% | +102.7% | -157.6 pp |
| 1 year | +82.1% | +140.5% | +58.3 pp |
| 3-year CAGR | — | +33.1% | — |
| 5-year CAGR | +22.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 89.62M USD
- Year-over-year change
- +82.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.62M | +82.1% |
| FY2024 | 2024-12-31 | 49.21M | +199.6% |
| FY2023 | 2023-12-31 | (49.41M) | -379.7% |
| FY2022 | 2022-12-31 | (10.3M) | +83.3% |
| FY2021 | 2021-12-31 | (61.82M) | — |
EBITDA vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 EBITDA of $129.77M is the highest of the 10 companies compared; the peer median is -$45.4M.
- Its year-over-year change of +184.0% is the 2nd highest of 10, against a peer median of -16.7%.
- EBITDA amounts to 23.1% of revenue for VCYT, versus a peer median of 19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $129.77M | +184.0% | — | 23.1% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$725.67K | -101.8% | — | 0.2% | |
| LTM Mar 2026 | -$18.34M | +33.2% | — | 19.1% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M | +19.5% | — | 2329.5% |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$76.43M | -374.1% | — | 16.8% |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
| Peer median (excluding VCYT) | -$45.4M | -16.7% | — | 19.1% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.